Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Castle Biosciences, Inc.
Castle Biosciences, Inc. News
Castle Biosciences, Inc. Quantitative Score
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Castle Biosciences, Inc. Financials
Table Compare
Compare CSTL metrics with: | |||
|---|---|---|---|
Earnings & Growth | CSTL | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CSTL | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CSTL | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CSTL | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Castle Biosciences, Inc. Income
Castle Biosciences, Inc. Balance Sheet
Castle Biosciences, Inc. Cash Flow
Castle Biosciences, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Castle Biosciences, Inc. Executives
| Name | Role |
|---|---|
| Mr. Derek J. Maetzold | Founder, Chief Executive Officer, President & Director |
| Ms. Kristen M. Oelschlager R.N. | Chief Operating Officer |
| Mr. Frank Stokes | Chief Financial Officer & Treasurer |
| Mr. Tobin W. Juvenal | Chief Commercial Officer |
| Dr. Matthew Goldberg M.D. | Senior Vice President of Medical |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Derek J. Maetzold | Founder, Chief Executive Officer, President & Director | Male | 1962 | 1.66M |
| Ms. Kristen M. Oelschlager R.N. | Chief Operating Officer | Female | 1968 | 1.21M |
| Mr. Frank Stokes | Chief Financial Officer & Treasurer | Male | 1970 | 926.74K |
| Mr. Tobin W. Juvenal | Chief Commercial Officer | Male | 1961 | 883.19K |
| Dr. Matthew Goldberg M.D. | Senior Vice President of Medical | -- |
Castle Biosciences, Inc. Insider Trades
| Date | 27 Jun |
| Name | MAETZOLD DEREK J |
| Role | Pres. & Chief Exec. Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 4944 |
| Date | 27 Jun |
| Name | MAETZOLD DEREK J |
| Role | Pres. & Chief Exec. Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 8068 |
| Date | 27 Jun |
| Name | MAETZOLD DEREK J |
| Role | Pres. & Chief Exec. Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 6924 |
| Date | 27 Jun |
| Name | MAETZOLD DEREK J |
| Role | Pres. & Chief Exec. Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 660 |
| Date | 27 Jun |
| Name | MAETZOLD DEREK J |
| Role | Pres. & Chief Exec. Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 660 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 27 Jun | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Disposed | S-Sale | 4944 |
| 27 Jun | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Disposed | S-Sale | 8068 |
| 27 Jun | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Disposed | S-Sale | 6924 |
| 27 Jun | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Disposed | S-Sale | 660 |
| 27 Jun | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Disposed | S-Sale | 660 |